Table 6 Specificity results of amivantamab
S. no | Sample ID | Intensity (cps) | % Interference | Pass/fail | ||
|---|---|---|---|---|---|---|
Amivantamab | Trastuzumab | Amivantamab | Trastuzumab | |||
1 | Std Blank 1 | 0 | 0 | 0 | 0 | Pass |
2 | LLOQ 1 (5 ng/ml) | 0.369 × 105 | 4.237 × 105 | 0 | 0 | Pass |
3 | Std Blank 2 | 0 | 0 | 0 | 0 | Pass |
4 | LLOQ 2 (5 ng/ml) | 0.361 × 105 | 4.221 × 105 | 0 | 0 | Pass |
5 | Std Blank 3 | 0 | 0 | 0 | 0 | Pass |
6 | LLOQ 3 (5 ng/ml) | 0.365 × 105 | 4.234 × 105 | 0 | 0 | Pass |
7 | Std Blank 4 | 0 | 0 | 0 | 0 | Pass |
8 | LLOQ 4 (5 ng/ml) | 0.367 × 105 | 4.225 × 105 | 0 | 0 | Pass |
9 | Std Blank 5 | 0 | 0 | 0 | 0 | Pass |
10 | LLOQ 5 (5 ng/ml) | 0.363 × 105 | 4.211 × 105 | 0 | 0 | Pass |
11 | Std Blank 6 | 0 | 0 | 0 | 0 | Pass |
12 | LLOQ 6 (5 ng/ml) | 0.364 × 105 | 4.240 × 105 | 0 | 0 | Pass |